IMMUNOTHERAPY

Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, comments on the changing landscape of immunotherapies for the treatment of melanoma.

James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan-Kettering Cancer Center, discusses emerging treatment options for patients with kidney cancer.

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, discusses the differences between the CAR-modified T cells of three institutions.

Matthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carincoma, Yale New Haven Hospital, discusses the difference between adverse events caused by chemotherapy and immunotherapy.

William Kevin Kelly, DO, professor of medical oncology and urology, Thomas Jefferson University, discusses the possibility of preselecting which castration-resistant prostate cancer (CRPC) patients will be sensitive to chemotherapy or hormone therapy.

At the 10th International Meeting of the Society for Melanoma Research, researchers provided insight into combination treatments and immunotherapies for the treatment of melanoma.

Naiyer A. Rizvi, MD, discusses the phenomenon of pseudoprogression in patients with lung cancer after they receive immunotherapy treatment.

Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, discusses the difference between blocking PD-1 and PD-L1 in melanoma.

T-VEC, a novel oncolytic immunotherapy derived from the herpes simplex virus type 1, demonstrated a significant improvement in DRR, the primary endpoint in a pivotal phase III trial in patients with stage IIIB-IV melanoma.

MPDL3280A produced durable responses in studies in patients with forms of locally advanced/metastatic cancers, including smokers with NSCLC who customarily have poorer responses to cancer therapies than nonsmokers.

The use of cancer immunotherapies has evolved. The latest immunotherapies are not only effective, but also accessible enough to be administered not just by expert immunologists, but by general oncologists.

Targeted Therapies spoke with Suzanne Topalian, MD, professor of Surgery and Oncology at Johns Hopkins University School of Medicine, about the progress and promise of PD-1 targeted cancer therapy.

Targeted Oncology spoke with Antoni Ribas, MD, PhD, director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, about the emerging role for immunotherapy in cancer.

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan-Kettering Cancer Center, discusses PD-1 and PD-L1 antibodies in development for the treatment of lung cancer.

Jeffrey A. Sosman, MD, from the Vanderbilt University School of Medicine and Vanderbilt-Ingram Cancer Center, discusses the use of checkpoint inhibitors in cancer care.

PD-L1 expression in tumors is a candidate molecular marker warranting further investigation as a means to select patients for immunotherapy with an anti PD-1 antibody

Concurrent nivolumab and ipilimumab produced “rapid and deep” responses in patients with advanced melanoma who took part in the first phase I trial to evaluate the PD-1-blocking antibody nivolumab, along with the CTLA-4-blocking antibody ipilimumab.

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the outlook for immunotherapies in cancer care.

Julie R. Brahmer, MD, explains the role of the PD-1 pathway and the ligands PD-L1 and PD-L2 in the regulation of the immune system.

Omid Hamid, MD, discusses promising combination therapies for the treatment of melanoma.

Michael Birrer, MD, PhD, professor of medicine, Harvard Medical School, director, Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, discusses other targets in ovarian cancer besides PARP.

The PD-1 blocking antibody nivolumab continues to demonstrate clinical activity in previously treated patients with advanced non-small cell lung cancer (NSCLC), according to updated long-term survival data from a phase I trial.

Russell J. Schilder, MD, discusses new therapeutics and their role in gynecologic cancers.

Targeted Oncology spoke with Padmanee Sharma, MD, PhD, about advances in immunotherapy for castration-resistant prostate cancer (CRPC).

Jeffrey A. Sosman, MD, professor of medicine, director, Melanoma and Tumor Immunotherapy Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, discusses immune response in renal cell carcinoma.